Daiichi Sankyo has participated in Access Accelerated, an initiative through which 24 pharmaceutical companies from Japan, the United States, and Europe to improve prevention, diagnosis, and treatment for NCDs* in low and lower-middle income countries in partnership with The World Bank Group and the Union for International Cancer Control.

Access Accelerated is working toward achieving one of the targets under Goal 3 of the SDGs, specifically, “by 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.”

*Non-communicable disease, such as cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes.

Please see a video message from CEO at the time.

In May 2018, the Year One Report summarizing activities in the initial year of Access Accelerated was published.
Year Two Report was published in June 2019.
Year One Report and Year Two Report contain a report on our past healthcare personnel development activities in China.
In 2019, new Access Accelerated activities were commenced in Myanmar
For details on the Access Accelerated activities, refer to the following website.